Evidence map›Paper›PMID 35832118›Full record

ArticleInternational journal of nanomedicine2022

GOx-Functionalized Platelet Membranes-Camouflaging Nanoreactors for Enhanced Multimodal Tumor Treatment.

Ying Du, Shujun Wang, Jianfeng Luan, Meilin Zhang, Baoan Chen, Yanfei Shen

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ying DuDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Shujun WangDepartment of Blood Transfusion, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, People's Republic of China.
Jianfeng LuanDepartment of Blood Transfusion, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, People's Republic of China.
Meilin ZhangDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0002-4684-2647
Baoan Chen *Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Yanfei Shen *School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Zhongda Hospital Southeast University · CNNanjing General Hospital of Nanjing Military Command · CNSoutheast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucose oxidase (GOx)-based starvation therapy is a new cancer treatment strategy. However, the characteristics such as limited curative effect and hypoxic tumor environment hinder its further application seriously. Methods: Herein, doxorubicin (DOX) loaded in hollow mesoporous copper sulfide (HMCuS) nanoparticles assembled with manganese dioxide (HMMD) as nanoshell was prepared. We developed a targeted enhanced cancer treatment method to camouflage HMMD by GOx-functionalized platelet (PLT) membranes (HMMD@PG). Results: GOx can be specially transported to the tumor site with PLT membrane for effective starvation treatment. Glucose and oxygen (O Conclusion: This work broadens the application mode of GOx and shows the new development of a multi-mode collaborative processing system of nanoplatforms based on cell membrane camouflage.

Indexed as

NanoparticlesNeoplasmsCell Line, TumorDoxorubicinGlucose OxidaseHumansHydrogen PeroxideManganese CompoundsNanotechnologyOxidesSulfidesTumor MicroenvironmentDoxorubicinGlucose OxidaseHydrogen PeroxideManganese CompoundsOxidesSulfidesglucose oxidasenanoparticlesPLT membranetumor microenvironmenttumor treatment

Identifiers

PMID35832118
PMCPMC9273187
OpenAlexW4285506718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.